EUVIMEDEUVIMED entdecken
Crossref

Safety and Efficacy of Cyclophosphamide With Dual Mecapegfilgrastim and On‐Demand Plerixafor for Salvage Mobilization in Patients With Initial Mobilization Failure: A Retrospective Cohort

Fang Huang, Ke Cui, Jie Zhao, Zhichao Li, Yun Qin, Siguo Hao, Jiangbo Wan

Journal of Clinical Apheresis · 2026

DOI: 10.1002/jca.70091 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Apheresis, 2026. Verfasst von Fang Huang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Mobilization, Cyclophosphamide, Benzylamines, Cyclams. Die Arbeit nennt 18 Literaturangaben. Gefördert von: The Medical Industrial Crossroads Research Fund from Shanghai Jiaotong University, Clinical Innovation Project from Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Initial hematopoietic stem cell (HSC) mobilization failure remains a critical barrier to autologous stem cell transplantation (ASCT) in patients with lymphoma or multiple myeloma (MM). This retrospective cohort study (August 2015 to March 2023) evaluated the efficacy, safety, and cost‐effectiveness of a novel salvage regimen—split‐dose cyclophosphamide (CTX: 1.5 g/m 2 for 2 days) + Mecapegfilgrastim (PEG‐rhG‐CSF) + on‐demand plerixafor (PXF)—compared to conventional strategies (CTX + granulocyte colony‐stimulating factor [G‐CSF] or G‐CSF + PXF) in 118 patients with initial mobilization failure. Patients were stratified into three groups: CTX + PEG‐rhG‐CSF + on‐demand PXF ( n = 46), CTX + G‐CSF ( n = 34), and G‐CSF + PXF ( n = 38). The CTX + PEG‐rhG‐CSF + on‐demand PXF group achieved superior mobilization efficacy: median CD34 + cell yield was 9.2 × 10 6 /kg, which is significantly higher than that of CTX + G‐CSF group (4.1 × 10 6 /kg; p < 0.05) and G‐CSF + PXF group (4.6 × 10 6 /kg; p < 0.05). Rates of achieving the thresholds of ≥ 2 × 10 6 CD34 + cells/kg and ≥ 5 × 10 6 CD34 + cells/kg were significantly higher in the CTX + PEG‐rhG‐CSF + on‐demand PXF group. This superior mobilization efficacy also brought fewer apheresis sessions: only 15.2% of patients in the CTX + PEG‐rhG‐CSF + on‐demand PXF cohort required ≥ 2 sessions, compared to 70.5% in CTX + G‐CSF group and 57.9% in G‐CSF + PXF group ( p < 0.001). Safety profiles were comparable across cohorts: febrile neutropenia occurred in 13% of patients in CTX + PEG‐rhG‐CSF + on‐demand PXF group (vs. 26.5% in CTX + G‐CSF; p = 0.33). Severe neutropenia (Grade 3–5) was common in CTX‐containing groups (91.3% vs. 90.2%; p = 0.88) but mostly being transient, with no treatment‐related mortality. Neutrophil engraftment times were similar (median 10–11 days; p = 0.406) in all groups. Cost analysis revealed that the CTX + PEG‐rhG‐CSF + on‐demand PXF regimen was more cost‐effective than G‐CSF + PXF regimen (5511 vs. 8761; p < 0.05) but more expensive than CTX + G‐CSF regimen ($3012; p < 0.05). In conclusion, CTX + PEG‐rhG‐CSF + on‐demand PXF is a highly effective salvage mobilization strategy for patients with initial HSC mobilization failure, yielding higher CD34 + cell counts with fewer aphereses and acceptable safety. With balanced advantages in efficacy, safety, and cost‐effectiveness, the CTX + PEG‐rhG‐CSF + on‐demand PXF regimen can be a preferred salvage option for ASCT candidates with prior mobilization failure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell MobilizationCyclophosphamideBenzylaminesCyclamsSalvage TherapyFilgrastimHeterocyclic CompoundsHumansRetrospective StudiesGranulocyte Colony-Stimulating FactorFemaleMaleMiddle AgedPolyethylene GlycolsAdultHematopoietic Stem Cell TransplantationAgedLymphomaMultiple Myeloma

Stichwörter der Autor:innen

MecapegfilgrastimPlerixaforautologous stem cell transplantationhematopoietic stem cell mobilizationsalvage therapy

Substanzen

CyclophosphamideGranulocyte Colony-Stimulating FactorplerixaforBenzylaminesCyclamsFilgrastimPolyethylene GlycolsHeterocyclic Compounds

Autor:innen und Institutionen

  • Department of Hematology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.

Förderung

  • The Medical Industrial Crossroads Research Fund from Shanghai Jiaotong University
  • Clinical Innovation Project from Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Zitieren

APA

Huang, F., Cui, K., Zhao, J., Li, Z., Qin, Y., Hao, S., & Wan, J. (2026). Safety and Efficacy of Cyclophosphamide With Dual Mecapegfilgrastim and On‐Demand Plerixafor for Salvage Mobilization in Patients With Initial Mobilization Failure: A Retrospective Cohort. Journal of Clinical Apheresis. https://doi.org/10.1002/jca.70091

Vancouver

Huang F, Cui K, Zhao J, Li Z, Qin Y, Hao S, et al. Safety and Efficacy of Cyclophosphamide With Dual Mecapegfilgrastim and On‐Demand Plerixafor for Salvage Mobilization in Patients With Initial Mobilization Failure: A Retrospective Cohort. Journal of Clinical Apheresis. 2026. doi:10.1002/jca.70091

BibTeX
@article{Huang2026,
  author = {Huang, Fang and Cui, Ke and Zhao, Jie and Li, Zhichao and Qin, Yun and Hao, Siguo and Wan, Jiangbo},
  title = {Safety and Efficacy of Cyclophosphamide With Dual Mecapegfilgrastim and On‐Demand Plerixafor for Salvage Mobilization in Patients With Initial Mobilization Failure: A Retrospective Cohort},
  journal = {Journal of Clinical Apheresis},
  year = {2026},
  doi = {10.1002/jca.70091}
}
Kostenlos starten →